WuXi NextCODE (Shanghai) Biotechnology Co., Ltd. (WuXi NextCODE) is a leader in the field of precision medicine in China, and it's committed to improving human health by using precision medical big data. In January 2015, WuXi AppTech, a Shanghai biomedical platform company, acquired WuXi NextCODE Health, a company with a world-leading platform for gene sequencing analysis tools. Then WuXi NextCODE Health was merged with AppTech Genomics Center to form the WuXi NextCODE (Shanghai) Biotechnology Co., Ltd..
Headquartered in Shanghai, WuXi NextCODE establishes branches in Beijing, Nanjing, Chengdu, Zhengzhou, Guangzhou, Nanning, and Shijiazhuang, which provide comprehensive precision medicine solutions for researchers, clinicians, health organizations, and individual consumers. At the same time, the company helps partners accelerate drug R&D and diagnostic reagent development, reduce human birth defects, and improve diagnosis of rare diseases and other clinical applications of precision medicine.
WuXi NextCODE, with a localized global layout, operates physical standardized management platforms for genome big data in China, the United States and Europe, and it is always at the forefront of international precision medicine research. It has undertaken national precision medicine projects in Iceland, the United Kingdom and other countries, and participated in precision medicine projects in China and the United States.
WuXi NextCODE takes the lead in meeting international quality standards. It has the first laboratory in China that has passed both US CLIA/CAP certification and ISO 15189 certification. As an integrated gene R&D application and big data empowerment platform, it supports cloud use and offline use.
WuXi NextCODE has established internationally advanced high-throughput gene sequencing platforms, including Illumina NovaSeq, Illumina HiSeq X Ten, Ion Torrent, and Nanopore. It also purchased automated instrument operation systems from companies such as Agilent and Hamilton, for genome-wide sequencing, whole exome sequencing, transcriptome sequencing, targeted sequencing, tumor hotspot mutations, etc. All these enable it to offer a full range of clinical or research-level sequencing services. The company has strong data processing capabilities and unique lossless data storage and compression capabilities to ensure efficient production of genomic big data.
WuXi NextCODE is possessed of powerful bioinformatics analysis tools and it has built the first precision medical cloud platform in China. NextCODE, a precision medical big data analysis and interpretation system, is the only data analysis system that has been validated and optimized by population-wide genome-wide data. As China's first precision medical big data cloud platform, NextCODE aims to build a nationwide, standardized, safe and reliable precision medical big data cloud platform. It strives to promote concentration and application of domestic genomic information and precision medical big data, and facilitate exchanges and cooperation in the field of precision medicine among relevant government departments, the medical industry, academia and industry, so as to comprehensively develop China's precision medicine industry.
In the future, WuXi NextCODE, by carrying out more extensive and in-depth cooperation with platforms and projects on an international scale, is committed to empowering China's precision medicine and jointly contributing to global medical development.